You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameButethal
Accession NumberDB01353
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionButethal is a sedative and a hypnotic drug.
Structure
Thumb
Synonyms
Butethal
Butobarbital
Butobarbitone
Neonal
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NeonalNot Available
SonerylNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIOHZ8QAW6YC
CAS number77-28-1
WeightAverage: 212.2456
Monoisotopic: 212.116092388
Chemical FormulaC10H16N2O3
InChI KeyInChIKey=STDBAQMTJLUMFW-UHFFFAOYSA-N
InChI
InChI=1S/C10H16N2O3/c1-3-5-6-10(4-2)7(13)11-9(15)12-8(10)14/h3-6H2,1-2H3,(H2,11,12,13,14,15)
IUPAC Name
5-butyl-5-ethyl-1,3-diazinane-2,4,6-trione
SMILES
CCCCC1(CC)C(=O)NC(=O)NC1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBarbituric acid derivatives
Alternative Parents
Substituents
  • Barbiturate
  • Ureide
  • 1,3-diazinane
  • Urea
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of insomnia.
PharmacodynamicsButethal (also known as butobarbitone and butobarbital) belongs to a group of medicines called the barbiturates. It is thought to act on receptors in the brain (GABA receptors) causing the release of the chemical GABA. This chemical inhibits certain areas of the brain resulting in sleepiness.
Mechanism of actionButethal binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. All of these effects are associated with marked decreases in GABA-sensitive neuronal calcium conductance (gCa). The net result of barbiturate action is acute potentiation of inhibitory GABAergic tone. Barbiturates also act through potent (if less well characterized) and direct inhibition of excitatory AMPA-type glutamate receptors, resulting in a profound suppression of glutamatergic neurotransmission.
Related Articles
AbsorptionRapidly absorbed following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half life37 hours
ClearanceNot Available
ToxicitySigns of overdose include confusion (severe), decrease in or loss of reflexes, drowsiness (severe), fever, irritability (continuing), low body temperature, poor judgment, shortness of breath or slow or troubled breathing, slow heartbeat, slurred speech, staggering, trouble in sleeping, unusual movements of the eyes, weakness (severe).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9222
Blood Brain Barrier+0.9712
Caco-2 permeable-0.5923
P-glycoprotein substrateSubstrate0.601
P-glycoprotein inhibitor INon-inhibitor0.684
P-glycoprotein inhibitor IINon-inhibitor0.968
Renal organic cation transporterNon-inhibitor0.9116
CYP450 2C9 substrateNon-substrate0.7899
CYP450 2D6 substrateNon-substrate0.9146
CYP450 3A4 substrateNon-substrate0.739
CYP450 1A2 substrateNon-inhibitor0.9149
CYP450 2C9 inhibitorNon-inhibitor0.8109
CYP450 2D6 inhibitorNon-inhibitor0.9343
CYP450 2C19 inhibitorNon-inhibitor0.7678
CYP450 3A4 inhibitorNon-inhibitor0.9762
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9528
Ames testNon AMES toxic0.6449
CarcinogenicityNon-carcinogens0.8975
BiodegradationNot ready biodegradable0.947
Rat acute toxicity3.0258 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9709
hERG inhibition (predictor II)Non-inhibitor0.8922
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point128.5 °CPhysProp
water solubility4880 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.73HANSCH,C ET AL. (1995)
logS-1.64ADME Research, USCD
pKa7.86SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility1.27 mg/mLALOGPS
logP1.65ALOGPS
logP1.61ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)8.48ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity53.45 m3·mol-1ChemAxon
Polarizability21.62 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05CA03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Butethal is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Butethal is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Butethal is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Butethal is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Butethal is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Butethal is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Butethal.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Butethal is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Butethal.
AmisulprideThe risk or severity of adverse effects can be increased when Butethal is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Butethal is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Butethal.
AmoxapineThe risk or severity of adverse effects can be increased when Butethal is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Butethal is combined with Amperozide.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Butethal.
ArticaineThe risk or severity of adverse effects can be increased when Butethal is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Butethal is combined with Asenapine.
AzaperoneThe risk or severity of adverse effects can be increased when Butethal is combined with Azaperone.
AzelastineButethal may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Butethal.
BaclofenThe risk or severity of adverse effects can be increased when Butethal is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Butethal is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Butethal.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Butethal is combined with Benzyl alcohol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Butethal is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butethal.
BrimonidineThe risk or severity of adverse effects can be increased when Butethal is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Butethal is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Butethal is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Butethal is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Butethal.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Butethal.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Butethal.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Butethal.
ButacaineThe risk or severity of adverse effects can be increased when Butethal is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Butethal is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Butethal is combined with Butamben.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Butethal.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Butethal.
CarbinoxamineThe risk or severity of adverse effects can be increased when Butethal is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Butethal is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Butethal is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Butethal is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Butethal is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Butethal.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Butethal.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Butethal.
ChlorphenamineThe risk or severity of adverse effects can be increased when Butethal is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Butethal.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Butethal.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Butethal is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Butethal.
CitalopramThe risk or severity of adverse effects can be increased when Butethal is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Butethal is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Butethal is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Butethal is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Butethal is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Butethal is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Butethal is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Butethal is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Butethal.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Butethal.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Butethal.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Butethal.
CyclizineThe risk or severity of adverse effects can be increased when Butethal is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butethal.
CyproheptadineThe risk or severity of adverse effects can be increased when Butethal is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Butethal is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butethal.
DapoxetineThe risk or severity of adverse effects can be increased when Butethal is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Butethal is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Butethal.
DesipramineThe risk or severity of adverse effects can be increased when Butethal is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Butethal is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Butethal is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Butethal is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Butethal.
DextromoramideThe risk or severity of adverse effects can be increased when Butethal is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Butethal.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Butethal.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Butethal.
DifenoxinThe risk or severity of adverse effects can be increased when Butethal is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Butethal is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Butethal is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Butethal is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Butethal is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Butethal.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Butethal.
DoramectinThe risk or severity of adverse effects can be increased when Butethal is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Butethal is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Butethal.
DoxylamineThe risk or severity of adverse effects can be increased when Butethal is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Butethal is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Butethal.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Butethal.
DrotebanolThe risk or severity of adverse effects can be increased when Butethal is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Butethal.
EcgonineThe risk or severity of adverse effects can be increased when Butethal is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Butethal is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Butethal is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Butethal.
EntacaponeThe risk or severity of adverse effects can be increased when Butethal is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Butethal is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Butethal.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Butethal.
EthanolButethal may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Butethal.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butethal.
EthosuximideThe risk or severity of adverse effects can be increased when Butethal is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Butethal is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Butethal is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Butethal is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Butethal is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Butethal is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Butethal is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Butethal is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Butethal.
EtoperidoneThe risk or severity of adverse effects can be increased when Butethal is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Butethal is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Butethal is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Butethal is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Butethal is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Butethal is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Butethal.
FexofenadineThe risk or severity of adverse effects can be increased when Butethal is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Butethal is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Butethal is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Butethal is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Butethal is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Butethal is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Butethal.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Butethal.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Butethal.
FluspirileneThe risk or severity of adverse effects can be increased when Butethal is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Butethal is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Butethal is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Butethal is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Butethal is combined with Fospropofol.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Butethal.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Butethal is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Butethal is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Butethal is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Butethal is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Butethal.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butethal.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Butethal.
HeroinThe risk or severity of adverse effects can be increased when Butethal is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Butethal is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Butethal.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Butethal.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Butethal.
HydroxyzineThe risk or severity of adverse effects can be increased when Butethal is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Butethal is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Butethal is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Butethal is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Butethal.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Butethal.
KetazolamThe risk or severity of adverse effects can be increased when Butethal is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Butethal is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Butethal is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Butethal is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Butethal.
LevocabastineThe risk or severity of adverse effects can be increased when Butethal is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Butethal is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Butethal is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Butethal.
LevomilnacipranThe risk or severity of adverse effects can be increased when Butethal is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Butethal.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Butethal.
LithiumThe risk or severity of adverse effects can be increased when Butethal is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Butethal is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Butethal is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Butethal.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Butethal.
Lu AA21004The risk or severity of adverse effects can be increased when Butethal is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Butethal is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Butethal.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Butethal is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Butethal is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Butethal is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Butethal is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Butethal.
MelperoneThe risk or severity of adverse effects can be increased when Butethal is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Butethal.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butethal.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Butethal.
MetaxaloneThe risk or severity of adverse effects can be increased when Butethal is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Butethal.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Butethal is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Butethal is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Butethal is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Butethal is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Butethal.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Butethal is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Butethal.
MethsuximideThe risk or severity of adverse effects can be increased when Butethal is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Butethal.
MetyrosineButethal may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Butethal.
MilnacipranThe risk or severity of adverse effects can be increased when Butethal is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butethal.
MirtazapineButethal may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Butethal.
MolindoneThe risk or severity of adverse effects can be increased when Butethal is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Butethal.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Butethal.
NabiloneThe risk or severity of adverse effects can be increased when Butethal is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Butethal.
NitrazepamThe risk or severity of adverse effects can be increased when Butethal is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Butethal is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Butethal is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Butethal is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Butethal is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Butethal is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Butethal.
OpiumThe risk or severity of adverse effects can be increased when Butethal is combined with Opium.
OrphenadrineButethal may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Butethal.
OsanetantThe risk or severity of adverse effects can be increased when Butethal is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Butethal.
OxprenololThe risk or severity of adverse effects can be increased when Butethal is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Butethal.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Butethal.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Butethal.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Butethal.
ParaldehydeButethal may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Butethal.
ParoxetineThe risk or severity of adverse effects can be increased when Butethal is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Butethal.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Butethal.
PerampanelThe risk or severity of adverse effects can be increased when Butethal is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Butethal is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Butethal.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Butethal.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Butethal.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Butethal is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Butethal is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Butethal.
PipamperoneThe risk or severity of adverse effects can be increased when Butethal is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Butethal is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Butethal is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Butethal is combined with Pomalidomide.
PramipexoleButethal may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Butethal is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Butethal is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Butethal.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Butethal.
PrimidoneThe risk or severity of adverse effects can be increased when Butethal is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Butethal.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butethal.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Butethal.
PromethazineThe risk or severity of adverse effects can be increased when Butethal is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Butethal.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Butethal.
PropoxycaineThe risk or severity of adverse effects can be increased when Butethal is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Butethal is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Butethal is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Butethal is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Butethal.
RamelteonThe risk or severity of adverse effects can be increased when Butethal is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Butethal.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Butethal.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Butethal.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Butethal.
RomifidineThe risk or severity of adverse effects can be increased when Butethal is combined with Romifidine.
RopiniroleButethal may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Butethal.
RotigotineButethal may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Butethal.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Butethal is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Butethal is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butethal.
SertindoleThe risk or severity of adverse effects can be increased when Butethal is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Butethal is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Butethal.
Sodium oxybateThe risk or severity of adverse effects can be increased when Butethal is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Butethal is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Butethal.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Butethal.
SuvorexantThe risk or severity of adverse effects can be increased when Butethal is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Butethal is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Butethal is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Butethal.
TetrabenazineThe risk or severity of adverse effects can be increased when Butethal is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Butethal is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Butethal is combined with Tetrodotoxin.
ThalidomideButethal may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Butethal.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Butethal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Butethal.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Butethal.
ThiothixeneThe risk or severity of adverse effects can be increased when Butethal is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Butethal is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Butethal is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Butethal is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Butethal is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Butethal is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Butethal.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Butethal is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Butethal.
TrazodoneThe risk or severity of adverse effects can be increased when Butethal is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Butethal.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Butethal.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Butethal.
TrimipramineThe risk or severity of adverse effects can be increased when Butethal is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Butethal is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Butethal.
VigabatrinThe risk or severity of adverse effects can be increased when Butethal is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Butethal is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Butethal is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Butethal is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Butethal.
ZiconotideThe risk or severity of adverse effects can be increased when Butethal is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Butethal is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Butethal.
ZolazepamThe risk or severity of adverse effects can be increased when Butethal is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Butethal.
ZonisamideThe risk or severity of adverse effects can be increased when Butethal is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Butethal.
ZotepineThe risk or severity of adverse effects can be increased when Butethal is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Butethal is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  3. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  4. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
  5. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  6. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
Gene Name:
CHRNA4
Uniprot ID:
P43681
Molecular Weight:
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Toxic substance binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
Gene Name:
CHRNA7
Uniprot ID:
P36544
Molecular Weight:
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ionotropic glutamate receptor activity
Specific Function:
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and t...
Gene Name:
GRIA2
Uniprot ID:
P42262
Molecular Weight:
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Kainate selective glutamate receptor activity
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIK2
Uniprot ID:
Q13002
Molecular Weight:
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Comments
comments powered by Disqus
Drug created on July 06, 2007 13:49 / Updated on August 17, 2016 12:23